Combinations of protein polysaccharide conjugate vaccines for intranasal immunization

Journal of Infectious Diseases

Volumn 186, Issue 9, 2002, Pages 1358-1361

  Ugozzoli, Mildred ^a   Mariani, Massimo ^a   Del Giudice, Giuseppe ^a   Soenawan, Elawati ^a   O'Hagan, Derek T ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTIBODY; DIPHTHERIA TOXIN; ESCHERICHIA COLI ENTEROTOXIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; POLYSACCHARIDE VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG CONJUGATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MUTANT; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL TOXINS; BACTERIAL VACCINES; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP C; POLYSACCHARIDES, BACTERIAL; VACCINES, CONJUGATE;

EID: 0036839283     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/344320     Document Type: Article

References (15)

1. Parkman PD. Combined and simultaneously administered vaccines: A brief history. Ann N Y Acad Sci 1995;754:1-9.
2. Eskola J, Olander RM, Hovi T, Litmanen L, Peltola S, Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine, Lancet 1996;348:1688-92.
3. Takahashi I, Marinaro M, Kiyono H, et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis 1996;173:627-35.
4. Pizza M, Giuliani MM, Fontana MR, et al. Mucosal vaccines: Non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001; 19:2534-41.
5. Bonenfant C, Dimier-Poisson I, Velge-Roussel F, et al. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect Immun 2001;69:1605-12.
6. Ghiara P, Rossi M, Marchetti M, et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun 1997;65:4996-5002.
7. Robbins JB. Vaccines for the prevention of encapsulated bacterial diseases: Current status, problems and prospects for the future. Immunochemistry 1978;15:839-54.
8. Constantino P, Viti S, Podda A, Velmonte MA, Nencioni L, Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992;10:691-8.
9. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95.
10. Pizza M, Domenighini M, Hol W, et al. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis. Mol Microbiol 1994;14:51-60.
11. Granoff DM, Maslanka SE, Carlone GM. et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998;5:479-85.
12. Ugozzoli M, O'Hagan DT, Ott GS. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: The effect of adjuvants on mucosal and serum antibody responses. Immunology 1998;93:563-71.
13. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969;129:1367-84.
14. Ugozzoli M, Santos G, Donnelly J, O'Hagan DT. Potency of a genetically toxoided mucosal adjuvant derived from the heat-labile enterotoxin of Escherichia coli (LTK63) is not adversely affected by the presence of preexisting immunity to the adjuvant. J Infect Dis 2001;183:351-4.
15. Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccine. J Control Release 2001;70:267-76.